Table 2.

Variables that may affect the level of evidence required for the clinical implementation of pharmacogenetics

	Level of Evidence Potentially Required
Variable	Higher	Lower
Genetic test	-Results not already available -Not available in-house -Slow return of results -High cost	-Results already available -Can be ordered in-house -Rapid return of results -Low cost
Genetic variant	-Rare -Low penetrance	-Common -High penetrance
Drug	-Cost of drug (or alternative) is low -Rarely used -Alternatives available	-Cost of drug (or alternative) is high -Commonly used -No alternatives available
Drug indication	-Mild -Rare	-Severe -Common
Adverse Outcome	-Mild -Rare	-Severe -Common
Setting	-Inpatient	-Outpatient
Patient	-Low risk for adverse outcome -Risk-averse	-High risk for adverse outcome -Risk-taking
Provider	-Risk-averse	-Risk-taking
Specialty	-Cardiology	-Oncology -Pediatrics
Stakeholder	-Health system -Payers	-Patients -Providers